Editorial Commentary
BRAFV600E mutant, PD-L1 TPS 90% NSCLC: 1st line treatment with targeted therapy
Precision Cancer Medicine
2021;
4:
10
.
(30 March 2021)
Editorial Commentary
The role of anti-PD-1/PD-L1 monotherapy as first-line treatment of metastatic NSCLC without targetable mutations and PD-L1 TPS 1–49%
Precision Cancer Medicine
2021;
4:
9
.
(30 March 2021)
Editorial Commentary
Management of acquired resistance to ALK inhibitors: repeat biopsy to characterize mechanisms of resistance does not significantly impact clinical outcomes
Precision Cancer Medicine
2021;
4:
8
.
(30 March 2021)
Editorial Commentary
Concerns and controversies regarding ipilimumab-based immunotherapy in the first-line treatment of non-small cell lung cancer
Precision Cancer Medicine
2021;
4:
7
.
(30 March 2021)
Editorial Commentary
ADAURA: the role of adjuvant EGFR TKI and future consideration (Pro)
Precision Cancer Medicine
2021;
4:
6
.
(30 March 2021)
Case Report
Precision oncology in EGFR positive non-small cell lung cancer: breaking the 10-year barrier—a case report
Precision Cancer Medicine
2021;
4:
5
.
(30 March 2021)
Case Report
Unusual pattern of recurrence and atypical visceral metastases in extremity soft tissue sarcoma: a case report
Precision Cancer Medicine
2021;
4:
4
.
(30 March 2021)
Review Article
A narrative review of immune checkpoint inhibitors in early stage triple negative breast cancer
Precision Cancer Medicine
2021;
4:
3
.
(30 March 2021)
Original Article
Anti-proliferative and anti-migratory effects of EGFR and c-Met tyrosine kinase inhibitors in triple negative breast cancer cells
Precision Cancer Medicine
2021;
4:
2
.
(30 March 2021)
Review Article
The role of immunotherapy in metastatic triple negative breast cancer: a narrative review of the current clinical trials
Precision Cancer Medicine
2021;
4:
1
.
(30 March 2021)